These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 23811602)

  • 21. Fluvastatin prevents development of arterial stiffness in haemodialysis patients with type 2 diabetes mellitus.
    Ichihara A; Hayashi M; Ryuzaki M; Handa M; Furukawa T; Saruta T
    Nephrol Dial Transplant; 2002 Aug; 17(8):1513-7. PubMed ID: 12147804
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Improving Arterial Wall Characteristics in Patients After Myocardial Infarction with a Very Low Dose of Fluvastatin and Valsartan: A Proof-of-Concept Study.
    Turk Veselič M; Eržen B; Hanžel J; Piletič Ž; Šabovič M
    Med Sci Monit; 2018 Sep; 24():6892-6899. PubMed ID: 30266894
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term effects of angiotensin II receptor blockade with valsartan on carotid arterial stiffness and hemodynamic alterations in patients with essential hypertension.
    Okura T; Watanabe S; Kurata M; Koresawa M; Irita J; Enomoto D; Jotoku M; Miyoshi K; Fukuoka T; Higaki J
    Clin Exp Hypertens; 2008 Jul; 30(5):415-22. PubMed ID: 18633763
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial.
    Derosa G; Cicero AE; Bertone G; Piccinni MN; Ciccarelli L; Roggeri DE
    Clin Ther; 2004 Oct; 26(10):1599-607. PubMed ID: 15598476
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Valsartan improves resting skin blood flow in type 2 diabetic patients and reduces poly(adenosine diphosphate-ribose) polymerase activation.
    Shrikhande G; Khaodhiar L; Scali S; Lima C; Hubbard M; Dudley K; Ganda O; Ferran C; Veves A
    J Vasc Surg; 2006 Apr; 43(4):760-70; discussion 770-1. PubMed ID: 16616233
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sub-therapeutic doses of fluvastatin and valsartan are more effective than therapeutic doses in providing beneficial cardiovascular pleiotropic effects in rats: A proof of concept study.
    Janić M; Lunder M; France Štiglic A; Jerin A; Skitek M; Černe D; Marc J; Drevenšek G; Šabovič M
    Vascul Pharmacol; 2017 Dec; 99():45-52. PubMed ID: 28951255
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Beneficial effects of combination of valsartan and amlodipine on salt-induced brain injury in hypertensive rats.
    Dong YF; Kataoka K; Tokutomi Y; Nako H; Nakamura T; Toyama K; Sueta D; Koibuchi N; Yamamoto E; Ogawa H; Kim-Mitsuyama S
    J Pharmacol Exp Ther; 2011 Nov; 339(2):358-66. PubMed ID: 21807884
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combination pravastatin and valsartan treatment has additive beneficial effects to simultaneously improve both metabolic and cardiovascular phenotypes beyond that of monotherapy with either drug in patients with primary hypercholesterolemia.
    Koh KK; Lim S; Choi H; Lee Y; Han SH; Lee K; Oh PC; Sakuma I; Shin EK; Quon MJ
    Diabetes; 2013 Oct; 62(10):3547-52. PubMed ID: 23863812
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Selective angiotensin receptor antagonism with valsartan decreases arterial stiffness independently of blood pressure lowering in hypertensive patients.
    Nakamura T; Fujii S; Hoshino J; Saito Y; Mizuno H; Saito Y; Kurabayashi M
    Hypertens Res; 2005 Dec; 28(12):937-43. PubMed ID: 16671331
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of angiotensin II type 1 receptor blocker on blood pressure variability and cardiovascular remodeling in hypertensive patients on chronic peritoneal dialysis.
    Shigenaga A; Tamura K; Dejima T; Ozawa M; Wakui H; Masuda S; Azuma K; Tsurumi-Ikeya Y; Mitsuhashi H; Okano Y; Kokuho T; Sugano T; Ishigami T; Toya Y; Uchino K; Tokita Y; Umemura S
    Nephron Clin Pract; 2009; 112(1):c31-40. PubMed ID: 19342867
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
    McMurray J; Solomon S; Pieper K; Reed S; Rouleau J; Velazquez E; White H; Howlett J; Swedberg K; Maggioni A; Køber L; Van de Werf F; Califf R; Pfeffer M
    J Am Coll Cardiol; 2006 Feb; 47(4):726-33. PubMed ID: 16487836
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of fluvastatin in hyperlipidaemic patients with non-insulin-dependent diabetes mellitus.
    Jokubaitis LA; Knopp RH; Frohlich J
    J Intern Med Suppl; 1994; 736():103-7. PubMed ID: 7986302
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of the angiotensin II receptor blockers telmisartan versus valsartan in combination with hydrochlorothiazide: a large, confirmatory trial.
    White WB; Murwin D; Chrysant SG; Koval SE; Davidai G; Guthrie R
    Blood Press Monit; 2008 Feb; 13(1):21-7. PubMed ID: 18199920
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of supportive measures on drug adherence in patients with essential hypertension treated with valsartan: the randomized, open-label, parallel group study VALIDATE.
    Düsing R; Handrock R; Klebs S; Tousset E; Vrijens B
    J Hypertens; 2009 Apr; 27(4):894-901. PubMed ID: 19300114
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Low-dose metoprolol CR/XL and fluvastatin slow progression of carotid intima-media thickness: Main results from the Beta-Blocker Cholesterol-Lowering Asymptomatic Plaque Study (BCAPS).
    Hedblad B; Wikstrand J; Janzon L; Wedel H; Berglund G
    Circulation; 2001 Apr; 103(13):1721-6. PubMed ID: 11282901
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of amlodipine and valsartan on vascular damage and ambulatory blood pressure in untreated hypertensive patients.
    Ichihara A; Kaneshiro Y; Takemitsu T; Sakoda M
    J Hum Hypertens; 2006 Oct; 20(10):787-94. PubMed ID: 16810279
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Is the reno-protective effect of valsartan dose dependent? A comparative study of 80 and 160 mg day(-1).
    Saikawa T; Sasaki J; Biro S; Kono S; Otonari T; Ikeda Y;
    Hypertens Res; 2010 Sep; 33(9):886-91. PubMed ID: 20555331
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Coadministration of valsartan 160 and 320 mg and simvastatin 20 and 40 mg in patients with hypertension and hypercholesterolemia: a multicenter, 12-week, double-blind, double-dummy, parallel-group superiority study.
    Rump LC; Baranova E; Okopien B; Weisskopf M; Kandra A; Ferber P
    Clin Ther; 2008 Oct; 30(10):1782-93. PubMed ID: 19014834
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Modelling of blood pressure and total cardiovascular risk outcomes after second-line valsartan therapy: the BSCORE study.
    Lins R; Coen N; Aerts A; Macdonald K; Brié H; Hermans C; Shen YM; Lee C; Vancayzeele S; Mecum N; Abraham I
    Arch Cardiovasc Dis; 2011 Aug; 104(8-9):428-34. PubMed ID: 21944144
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Newly diagnosed and previously known diabetes mellitus and 1-year outcomes of acute myocardial infarction: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial.
    Aguilar D; Solomon SD; Køber L; Rouleau JL; Skali H; McMurray JJ; Francis GS; Henis M; O'Connor CM; Diaz R; Belenkov YN; Varshavsky S; Leimberger JD; Velazquez EJ; Califf RM; Pfeffer MA
    Circulation; 2004 Sep; 110(12):1572-8. PubMed ID: 15364810
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.